AngioDynamics Inc
NASDAQ:ANGO

Watchlist Manager
AngioDynamics Inc Logo
AngioDynamics Inc
NASDAQ:ANGO
Watchlist
Price: 9.6 USD -0.41% Market Closed
Market Cap: 389.9m USD

AngioDynamics Inc
Investor Relations

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 800 full-time employees. The company went IPO on 2004-05-27. Its devices are used in minimally invasive, image-guided procedures. Its product offerings include Endovascular Therapies, Oncology/Surgery (OS) and Vascular Access (VA). Its Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products (Core) and Venous Insufficiency. Its OS product offerings includes a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the Irreversible Electroporation (IRE) technology, the NanoKnife System. Its portfolio of VA products includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.

Show more
Loading

Earnings Calls

2024 Q3
Jan 4, 2024
Show Transcript
Previous
Next
Company Maintains Stability Amid Challenges
2024 Q3
Jan 4, 2024

The company continued to make progress with its HelpDesk product, which now boasts 1,121 paid customers and increasing ARPU, indicating higher value clients. They introduced 'Insights', an add-on for LiveChat with 80 paying customers, providing valuable data analysis. Monthly recurring revenues grew 2.2% year-over-year and improved quarter-over-quarter by 0.3%. There was a 13% year-over-year increase in cash flows. However, customer numbers weren't satisfactory, attributed to high churn, possibly due to economic downturn. An AI-based ChatBot was launched, and subscription plans were reviewed to better suit customer usage. The company foresees reduced cost pressure due to market changes. Churn is examined for links to competition, which, while present, isn't the main factor. Sales of annual plans at discounts caused some decrease in ARPU. Main competitors are strong companies offering simple solutions like tawk.to, Facebook, and large enterprises like LivePerson; the company positions itself amidst these as serving small to medium-sized enterprises.

Show Full Analysis

Management

Mr. James C. Clemmer
CEO, President & Director
No Bio Available
Mr. Stephen A. Trowbridge
Executive VP & CFO
No Bio Available
Mr. Chad T. Campbell
Senior VP and GM of Global Vascular Access & Oncology Business Unit
No Bio Available
Mr. Warren G. Nighan
Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain
No Bio Available
Ms. Laura Piccinini
Senior VP & GM of Endovascular Therapies and International
No Bio Available
Mr. Saleem M. Cheeks
Vice President of Communications
No Bio Available
Mr. Benjamin H. Davis
Senior Vice President of Business Development & Strategy
No Bio Available
Ms. Marna I. Bronfen-Moore
Senior Vice President of Human Resources
No Bio Available
Ms. Kim L. Seabury
Senior Vice President of Information Technology
No Bio Available
Mr. Juan Carlos Serna
Senior Vice President of Scientific & Clinical Affairs
No Bio Available

Contacts

Address
NEW YORK
Latham
14 Plaza Dr
Contacts